MedPath

Fludeoxyglucose F 18

These highlights do not include all the information needed to use Fludeoxyglucose F 18 Injection USP safely and effectively. See full prescribing information for Fludeoxyglucose F 18 Injection USP . Fludeoxyglucose F 18 Injection USP Initial U.S. Approval: 2005

Approved
Approval ID

153b650d-7b69-4880-a72a-a5f13059d248

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 4, 2023

Manufacturers
FDA

Mayo Clinic

DUNS: 167141923

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Fludeoxyglucose F-18

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code52670-551
Application NumberANDA203612
Product Classification
M
Marketing Category
C73584
G
Generic Name
Fludeoxyglucose F-18
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 4, 2023
FDA Product Classification

INGREDIENTS (2)

SODIUM CHLORIDEInactive
Quantity: 4.5 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
FLUDEOXYGLUCOSE F-18Active
Quantity: 240 mCi in 1 mL
Code: 0Z5B2CJX4D
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Fludeoxyglucose F 18 - FDA Drug Approval Details